Welcome to the Investor Relations page. If you are a member of the investment community with a question about Regeneron, please call our Investor Relations Line at (914) 345-7400.

For an e-mail response to your Regeneron investment question, please contact us at invest@regeneron.com.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has candidates in preclinical programs for other diseases and disorders.


Recent Events
Jan 13, 2010 28th Annual J.P. Morgan Healthcare Conference
PDF View Presentation
Dec 15, 2009 Deutsche Bank 2009 Biotech Boston Confab Conference
Dec 1, 2009 21st Annual Piper Jaffray Healthcare Conference
Recent Press Releases
Jan 7, 2010 Regeneron Announces Presentation at the 28th Annual J.P. Morgan Healthcare Conference
Print Print page     Email Email page

Stock Information

NASDAQ:REGN
$25.77   + 0.04
Feb 8, 2010
4:00 PM ET
Quotes delay at least 20min., by eSignal.
Stock price graph
3 Mo.   6 Mo.   1 Yr.

Shareholder Tools

Featured Report